Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions

  DREAM (N = 616) MENSA (N = 576) SIRIUS (N = 135) MUSCA (N = 551) Total (N = 1878)
Age, years, mean (SD) 48.6 (11.3) 50.1 (14.3) 49.9 (12.3) 50.9 (13.5) 49.8 (13.0)
Female, n (%) 387 (63) 329 (57) 74 (55) 325 (59) 1115 (59)
BMI, kg/m2, mean (SD) 28.5 (5.95) 27.8 (5.83) 28.7 (6.01) 28.2 (6.40) 28.2 (6.06)
Duration of asthma, years, mean (SD) 19.1 (14.3) 19.9 (13.8) 18.7 (13.1) 19.5 (14.8) 19.5 (14.2)
Number of exacerbations in the previous year, n (%)      
  ≤ 2 286 (46) 246 (43) 67 (50) 357 (65) 956 (51)
 3 154 (25) 141 (24) 20 (15) 96 (17) 411 (22)
  ≥ 4 176 (29) 189 (33) 48 (36) 98 (18) 511 (27)
Receiving maintenance OCS therapy at baseline, n (%) 188 (31) 144 (25) 135 (100) 131 (24) 598 (32)
% predicted pre-bronchodilator FEV1, mean (SD) 59.7 (15.89) 61.0 (17.99) 58.7 (17.75) 58.6 (16.04) 59.7 (16.75)
Blood eosinophil count, cells/µL, geometric mean (SD logs) 260 (0.957) 300 (0.950) 250 (1.081) 340 (0.943) 290 (0.966)
  1. BMI body mass index, FEV1 forced expiratory volume in 1 s, OCS oral corticosteroids, SD standard deviation